Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Skyepharma PLC (SKP)

  Print      Mail a friend       Annual reports

Monday 09 September, 2002

Skyepharma PLC

Licensing Agreement

Skyepharma PLC
09 September 2002

For Immediate Release                                       September 9, 2002


                          SOLARASE MARKETING AGREEMENT

LONDON, UK & MELBOURNE, AUSTRALIA, September 9, 2002 -- SkyePharma PLC (LSE:
SKP; Nasdaq: SKYE) and Meditech Research Limited (ASX: MTR) today announced a
reciprocal licensing agreement concerning Solarase, a topical therapy for the
pre-cancerous skin condition, actinic or solar keratosis, in certain Pacific Rim
territories. Solarase is approved by regulatory authorities in North America and
Europe. It is already marketed under licenses from SkyePharma by Shire
Pharmaceuticals in five European countries, including the UK, Germany and
Sweden, and in the US by Quintiles Transnational Inc.

SkyePharma acquired rights to Solarase in 1999 from the administrators of Hyal
Pharmaceuticals (Hyal), excluding those relating to certain Pacific Rim
territories owned by Meditech under a pre-existing agreement with Hyal. Under
the new agreement announced today, SkyePharma re-acquires these territorial
rights to the product Solarase from Meditech in return for an upfront payment, a
milestone on eventual product registration in Australia or New Zealand, and a
royalty on sales.

SkyePharma gains the exclusive right to manufacture and market or sublicense
Solarase in Australia, New Zealand, Singapore and Malaysia whilst Meditech
obtains equivalent rights in new territories; China, Taiwan, Indonesia and the
Philippines, countries which were not included under the previous agreement.
Each company will receive an identical royalty on sales made by the other
company in their allocated territory.

Michael Ashton, Chief Executive Officer of SkyePharma, commented, 'Australia is
the world's second largest skin cancer market after the US. We estimate that the
incidence of actinic keratosis, a pre-cancerous condition associated with over
exposure to the sun, is in the region of 20% of the population so this is an
important market for us. Solarase treatment has demonstrated complete or
significant global improvement in nearly 80% of patients. We will conduct an
additional clinical study in Australia before pursuing rapid product
registration using our clinical and regulatory expertise whilst seeking a
commercialisation partner to maximise market penetration.'

Meditech's Chief Executive Officer, Mr Chris Carter, noted; 'These arrangements
provide Meditech with much greater prospects for early realisation of
significant royalties on SkyePharma's sales of Solarase. By acquiring rights to
secure commercial agreements in China, Taiwan, Indonesia and the Philippines,
Meditech can take advantage of its working relationships with Asian companies to
access the market potential of these enormous populations.'

                                    - ENDS-

For further information please contact:

SkyePharma PLC
Michael Ashton, Chief Executive Officer                    +44 (0) 207 491 1777
Valerie Tate, Head of Investor Relations                   +44 (0) 207 491 1777
Sandra Haughton, US Investor Relations                        +1 (212) 753 5780
Buchanan Communications
(Tim Anderson / Nicola How)                                +44 (0) 207 466 5000

Chris Carter, Chief Executive Officer                           +61 3 9296 2026
Dr Tracey Brown, Director of Research &
Development                                                     +61 3 9905 3760

Notes to Editors

SkyePharma PLC uses its world-leading drug delivery technology to develop
easier-to-use and more effective formulations of drugs. The majority of
challenges faced in the formulation and delivery of drugs can be addressed by
one of the Company's proprietary technologies in the areas of oral, injectable,
inhaled and topical delivery, supported by enhanced solubilisation capabilities.
For more information, visit

Meditech specialises in research and development of carbohydrate technologies to
preferentially deliver therapeutic compounds to disease targets and enhance
cellular uptake whilst reducing or eliminating systemic involvement and
consequent unwanted side effects.  Earlier in the year, the Company obtained
very encouraging results from two Phase I trials of its HyACT  technology
formulated with widely used anticancer products.  or
Email: [email protected]

                      This information is provided by RNS
            The company news service from the London Stock Exchange          SFFWASESEFU                                                                                                                                                                                                                                                    

a d v e r t i s e m e n t